stableBearishPHARMACEUTICALS
FDA Pauses Regenxbio Gene Therapy Trial After Finding Spinal Masses
4 signals from 3 sources·Updated 28 days ago
Momentum
54/100
Affected tickers
RGNX
Summary
The FDA halted the RGX-121 clinical trial for Hunter syndrome following the discovery of spinal masses in five patients. While some reports characterize this as a severe safety failure, others frame it as a regulatory…
Impact
Contributing sources (4)
- FDA pauses Regenxbio gene therapy trial after finding masses on patient spines · statnews.com · 30 days ago
- FDA pauses Regenxbio gene therapy trial after finding masses on patient spines · statnews.com · 30 days ago
- Regenxbio faces second clinical hold this year, delaying FDA approval for Hunter syndrome therapy · endpts.com · 30 days ago
Get the full Trend Briefing
Impact. Contributing sources. Momentum and affected tickers. Every emerging narrative gets a structured briefing on Whisper Media.
Create your free accountTrend Briefings available on Pro ($69/mo)
Trend Briefings are AI-generated from public sources. They are not financial advice and do not predict outcomes. Always do your own research before making investment decisions.